Liu S, Guo J, Cheng X, Li W, Lyu S, Chen X
Front Immunol. 2022; 13:836226.
PMID: 35309318
PMC: 8931421.
DOI: 10.3389/fimmu.2022.836226.
Sierawska O, Malkowska P, Taskin C, Hrynkiewicz R, Mertowska P, Grywalska E
Int J Mol Sci. 2022; 23(2).
PMID: 35054900
PMC: 8775698.
DOI: 10.3390/ijms23020716.
Tamayo E, Alvarez P, Merino R
Int J Mol Sci. 2018; 19(12).
PMID: 30544541
PMC: 6321615.
DOI: 10.3390/ijms19123928.
Bollum L, Huse K, Oksvold M, Bai B, Hilden V, Forfang L
PLoS One. 2017; 12(5):e0177188.
PMID: 28489883
PMC: 5425193.
DOI: 10.1371/journal.pone.0177188.
Mao S, Yang W, Ai L, Li Z, Jin J
Tumour Biol. 2015; 36(12):9903-8.
PMID: 26168957
DOI: 10.1007/s13277-015-3700-z.
Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes.
Guo J, Canaff L, Rajadurai C, Fils-Aime N, Tian J, Dai M
Breast Cancer Res. 2014; 16(6):476.
PMID: 25499443
PMC: 4311507.
DOI: 10.1186/s13058-014-0476-9.
The FYVE domain of Smad Anchor for Receptor Activation (SARA) is required to prevent skin carcinogenesis, but not in mouse development.
Chang H, Lin Y, Tsai P, Liang C, Yan Y
PLoS One. 2014; 9(8):e105299.
PMID: 25170969
PMC: 4149420.
DOI: 10.1371/journal.pone.0105299.
The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction.
Gonzalez E, Arms L, Vizzard M
Biomed Res Int. 2014; 2014:120525.
PMID: 24738044
PMC: 3971501.
DOI: 10.1155/2014/120525.
Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model.
Kim D, Walker R, Meltzer P, Cheng S
Carcinogenesis. 2013; 34(10):2389-400.
PMID: 23698635
PMC: 3786374.
DOI: 10.1093/carcin/bgt175.
Further Characterization of Activin A-induced IgA Response in Murine B Lymphocytes.
Lee H, Kim P
Immune Netw. 2010; 9(4):133-7.
PMID: 20157600
PMC: 2816946.
DOI: 10.4110/in.2009.9.4.133.
The family feud: turning off Sp1 by Sp1-like KLF proteins.
Lomberk G, Urrutia R
Biochem J. 2005; 392(Pt 1):1-11.
PMID: 16266294
PMC: 1317658.
DOI: 10.1042/BJ20051234.
Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas.
Amoroso S, Huang N, Roberts A, Potter M, Letterio J
Proc Natl Acad Sci U S A. 1998; 95(1):189-94.
PMID: 9419351
PMC: 18171.
DOI: 10.1073/pnas.95.1.189.
Transforming growth factor-beta (TGF beta) inhibition of Epstein-Barr virus (EBV)- and interleukin-4 (IL-4)-induced immunoglobulin production in human B lymphocytes.
Machold K, Carson D, Lotz M
J Clin Immunol. 1993; 13(3):219-27.
PMID: 8391546
DOI: 10.1007/BF00919975.
Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.
Grzegorzewski K, Ruscetti F, Usui N, Damia G, Longo D, Carlino J
J Exp Med. 1994; 180(3):1047-57.
PMID: 8064224
PMC: 2191629.
DOI: 10.1084/jem.180.3.1047.
Close correlation between the dephosphorylation of p53 and growth suppression by transforming growth factor-beta 1 in nasopharyngeal carcinoma cells transduced with adenovirus early region genes.
Mogi Y, Kato J, Horimoto M, Takimoto R, Murakami T, Hirayama A
Jpn J Cancer Res. 1994; 85(5):459-63.
PMID: 8014102
PMC: 5919502.
DOI: 10.1111/j.1349-7006.1994.tb02380.x.
DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective.
Allday M, Inman G, Crawford D, Farrell P
EMBO J. 1995; 14(20):4994-5005.
PMID: 7588628
PMC: 394603.
DOI: 10.1002/j.1460-2075.1995.tb00182.x.
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.
Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R
J Virol. 1988; 62(11):4173-84.
PMID: 2845129
PMC: 253849.
DOI: 10.1128/JVI.62.11.4173-4184.1988.
Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.
McCaffrey T, Falcone D, Brayton C, Agarwal L, Welt F, Weksler B
J Cell Biol. 1989; 109(1):441-8.
PMID: 2473082
PMC: 2115487.
DOI: 10.1083/jcb.109.1.441.
TGF-beta: problems and prospects.
Sporn M, Roberts A
Cell Regul. 1990; 1(12):875-82.
PMID: 2100192
PMC: 362858.
DOI: 10.1091/mbc.1.12.875.
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection.
Kekow J, Wachsman W, McCutchan J, Gross W, Zachariah M, Carson D
J Clin Invest. 1991; 87(3):1010-6.
PMID: 1999481
PMC: 329894.
DOI: 10.1172/JCI115059.